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Genome-wide association study of ulcerative colitis identifies
three new susceptibility loci, including the HNF4A region
The UK IBD Genetics Consortium and The Wellcome Trust Case Control Consortium 2
Abstract
Ulcerative colitis (UC) is a common form of inflammatory bowel disease with a complex
aetiology. As part of the Wellcome Trust Case Control Consortium 2, we performed a genome-
wide association scan for UC in 2361 cases and 5417 controls. Loci showing evidence of
association at P < 1 × 10−5 were followed up by genotyping in an independent set of 2321 cases
and 4818 controls. We find genome-wide significant evidence of association at three new loci,
each containing at least one biologically relevant candidate gene, on chromosomes 20q13
(HNF4A; P = 3.2 × 10−17), 16q22 (CDH1 and CDH3; P = 2.8 × 10−8) and 7q31 (LAMB1; 3.0 ×
10−8). Of note, CDH1 has recently been associated with susceptibility to colorectal cancer, which
is an established complication of longstanding UC. The new associations suggest that changes in
the integrity of the intestinal epithelial barrier may contribute to the pathogenesis of UC.
Genetic epidemiological data clearly implicate inherited susceptibility in the pathogenesis of
UC and Crohn's disease (CD), which represent the two common forms of inflammatory
bowel disease (IBD) and together affect at least 1 in 250 of the Northern European
population.1 Notwithstanding recent therapeutic advances, disease-related morbidity in
ulcerative colitis continues to be high. Recognized complications of severe disease
refractory to medical therapy include colectomy, often as an emergency, in 15-20% of
patients, as well as colorectal cancer2.
Substantial progress has been made in understanding IBD pathogenesis in recent years. In
genetically susceptible individuals it appears that a dysregulated mucosal immune response
to commensal enteric bacteria predisposes to chronic, relapsing intestinal inflammation
which is the hallmark of IBD.3 Clinical features combined with epidemiological evidence
have long suggested that CD and UC are related polygenic diseases. This has recently been
corroborated by the results of genetic association studies, which have highlighted both
disease-specific loci and others which are shared between UC and CD. For example, while
genetically-determined defects in the handling of intracellular bacteria (NOD2 and the
autophagy genes ATG16L1 and IRGM) are specific to CD, multiple components in the
Th17 pathway (IL23R, IL12B, JAK2, STAT3) are associated with both CD and UC.4-12
Until recently most attention had focused on CD, with genome-wide association (GWA)
studies and subsequent meta-analysis yielding more than 30 confirmed CD susceptibility
loci.4, 6, 7, 10-12 In addition to the longstanding known association in the MHC,13 the first
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GWA scans in UC reported associations at IL23R, IL10 and loci on chromosomes 1p36 and
12q15 which meet accepted genome-wide significance thresholds.14, 15
As part of the Wellcome Trust Case Control Consortium 2 (WTCCC2) study of 15 complex
disorders and traits, we report here the results of the largest GWA scan in UC to date. All
study subjects were UK residents of white, European ancestry; clinical data are presented in
Table 1. Cases and controls were genotyped on the Affymetrix 6.0 array. After application
of quality control filters (see Methods), we analysed GWA data from 2361 individuals with
UC and 5417 controls (Figure 1). An initial analysis revealed 24 distinct loci (comprising
156 SNPs) which showed evidence of association at P < 1×10−5. Sixteen of these had not
been previously reported, and were followed up by genotyping the most strongly associated
SNP from each locus using the Sequenom iPlex platform in an independent panel of 2321
UC cases and 4818 controls. Three new loci showed evidence for association at P < 5 × 10−8
in the combined panel, with three further new loci showing nominal (P < 0.05) replication
(Table 2 and Figure 2). We describe these loci below and highlight the most plausible
candidate gene for each, recognizing that fine mapping and functional studies are required to
define causal variants and identify the gene from which each signal arises. A list of all loci
for which replication was attempted is shown in Supplementary Table 1.
The most significant new association was seen at rs6017342 (GWA scan P = 3.2 × 10−13;
combined GWA and replication P = 8.5 × 10−17), which maps within a recombination
hotspot on chromosome 20q13 containing the 3′ untranslated region (UTR) of just one gene,
HNF4A. The SNP rs6017342 itself maps 5kb distal to the 3′UTR. Although within an
expressed sequence tag DB076868, this has been detected in just a single testis cDNA
library and does not encode a significant open reading frame. The region contains two small
blocks of sequence that are conserved in mammals and may include regulatory sequences
affecting the expression of surrounding genes. Since rs6017342 is located within a
recombination hotspot, there are few known SNPs in strong linkage disequilibrium (r2 > 0.5)
with it; there are none on the Affymetrix chip used in this study or on the Illumina chips
used in previous studies. As the evidence for this association rests on this single SNP, we
subjected these data to careful scrutiny; genotype cluster plots for this SNP showed clear
resolution of the 3 genotype classes (Supplementary Figure 1), with 99.3% completeness of
genotypes within this dataset.
Rare HNF4A mutations account for approximately 4% of UK cases of maturity-onset
diabetes of the young (MODY),16 a monogenic form of diabetes mellitus characterized by
autosomal dominant inheritance, young age of onset, pancreatic b-cell dysfunction and
sensitivity to sulphonylureas. Common variants of HNF4A influence predisposition to Type
II diabetes (rs2144908)17 and dyslipidaemia (rs1800961).18 The UC associated SNP,
rs6017342 is not in LD with either of these 2 common variants, nor did it not show
association in our study of CD (P=0.92).3
HNF4A encodes the transcription factor hepatocyte nuclear factor 4 α which regulates the
expression of multiple components within all three key compartments of the cell-cell
junction, namely the adherens junction, the tight junction and the desmosome.19 Such cell-
cell junctions are fundamental to epithelial organization and barrier function. HNF4α also
plays a key role in the development of the embryonic mammalian gastrointestinal tract.
Previous studies demonstrated that mice with targeted deletion of HNF4α in epithelial cells
of the foetal colon die perinatally. Histological analysis of colonic tissue recovered during
late development (E18.5) demonstrated absent crypt formation, reduced epithelial cell
proliferation and defective goblet cell maturation.20 In order to explore the role of HNF4α
in murine intestinal inflammation, Ahn and colleagues circumnavigated the embryonic
lethality of Hnf4α−/− mice by generating a conditional model of intestinal Hnf4α deletion.
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21 These Hnf4αΔIEpC mice (floxed Hnf4α driven by the villin promoter) developed
increased epithelial permeability and a markedly more severe colitis following dextran
sodium sulphate (DSS) challenge, than their wild-type littermates.21 The same investigators
provided preliminary evidence for dysregulated HNF4A gene expression in the intestinal
epithelium in Crohn's disease and in ulcerative colitis,21 a finding which now merits
detailed re-exploration.
Significant association was also seen for a locus on chromosome 16q22, with the strongest
signal at rs1728785 (GWA scan P = 1.8 × 10−5; combined GWA and replication P = 2.8 ×
10−8). The interval bounded by recombination hotspots spans 411 kb and encodes several
genes. Among the strongest candidates for UC susceptibility is CDH1 which encodes E-
cadherin. This transmembrane glycoprotein is one of the main components of the adherens
junction and a key mediator of intercellular adhesion in the intestinal epithelium. It also
plays a key role in epithelial restitution and repair following mucosal damage and expression
of CDH1 is known to be significantly reduced in areas of active UC.22
Given the well-recognised association between UC and colorectal cancer,2 the observation
of correlated association signals at the CDH1 locus in both diseases is striking. Thus variants
in LD (r2 = 0.5) with the most strongly UC associated SNP in our study were recently
identified in a GWA scan meta-analysis to be associated with colorectal cancer
susceptibility23; conversely, we find that a perfect proxy for the most associated SNP in the
colorectal cancer study is also associated with UC (P = 8 × 10−4). This locus did not show
association with CD in a large international GWA meta-analysis of CD (P = 0.549)6
(Supplementary Table 2). However, evidence for association of CDH1 with CD was
reported recently in the Canadian population using a candidate gene approach,24 and the CD
associated SNPs resulted in a truncated E-cadherin protein in vitro which accumulated in the
cytoplasm and led to disorganized epithelial architecture.24
Of great potential relevance is the evidence that HNF4A and E-cadherin co-operate to
maintain epithelial barrier integrity in the intestine. In experiments focused on the liver,
HNF4α knockout mice failed to express E-cadherin,19 while in the gut E-cadherin
dependent cell-cell contact was found to be critical in determining the amount and binding
activity of nuclear HNF4α. This in turn affected the expression of several genes including
ApoA-IV,25 an anti-inflammatory protein known to inhibit experimental colitis.26
The third newly confirmed UC susceptibility locus was a region on chromosome 7q31,
previously suggested by a recent North American GWA scan.14 In the current study the
peak association was seen at rs886774 (GWA scan P = 4.8 × 10−7; combined GWA and
replication P = 3.0 × 10−8). A strong positional candidate gene at this locus is LAMB1,
encoding the laminin beta 1 subunit. Laminins are heterotrimers; the beta-1 light chain is
present in laminins-1 -2 and -10. Laminins are expressed in the intestinal basement
membrane, and play a key role in anchoring the single-layered epithelium; expression is
known to be down-regulated in UC.27 rs886774 was not associated with CD in the meta-
analysis.5 (Supplementary Table 2)
Two other loci previously implicated in UC-related phenotypes showed strong (but not
genome-wide significant) association with UC. These comprise a SNP previously associated
with osteoporosis28 (rs7524102 on chromosome 1p36, combined GWA and replication P =
3.1 × 10−7) and a SNP nearby (though not in LD with) a marker known to be associated with
psoriasis29 (rs9548988 on 13q.13, combined GWA and replication P = 2.7 × 10−7).
In addition to the novel loci described above, our GWAS detected strong association at
established UC loci such as the MHC, IL23R, 3p21/MST1 and NKX2-3 (one tailed P values
in the direction of the previously reported association in Table 3). We also provide robust
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confirmation of two UC loci reported recently in genome-wide scans, the IL10 locus11 and
the OTUD3/PLA2G2E locus12 on chromosome 1q31 and 1p36 respectively. Also of
interest is our finding that the PSMG1 locus on chromosome 21, which has previously been
associated with pediatric-onset IBD,30 is likely to contribute specifically to disease
susceptibility in UC. Variable degrees of support were obtained for some previously
reported UC loci, including ECM1, CARD9,31 KIF21B/chromosome 1q32, and JAK2/
chromosome 9p24, but weaker support for other loci such as IL2/IL21,32 IL12B and 12q15
(Table 3). Some of the UC loci are clearly associated with CD, while others are not, or have
not been tested (Supplementary Table 2). We also tested for epistatic interaction among all
pairwise combinations of these loci (both previously described and new) but found none.
This is the first report of a new series of GWA scans undertaken by the WTCCC2
consortium. We have identified three new susceptibility loci for UC, and provide the first
genetic link between UC and colorectal cancer. Each of the strongest new association
intervals that we have identified contains respectively HNF4A, CDH1 and LAMB1 as the
most plausible positional candidate genes, thus providing further evidence for the re-
emerging concept that altered epithelial barrier function may be a key factor in UC
pathogenesis.8 Indeed, this is the first time that variants within genetic loci encoding such
epithelial barrier genes have shown association with IBD at stringent genome-wide
significant thresholds. Fine mapping and functional studies are clearly required to
investigate this connection further, but our study provides strong scientific justification for
the exploration of new therapeutic targets relevant to epithelial barrier function.
METHODS
Subjects
Cases—A total of 5319 unrelated patients of white, European, non-Jewish ancestry with a
diagnosis of ulcerative colitis established using standard endoscopic, radiological and
histological criteria, were recruited from ten centres within the United Kingdom
(Cambridge, Oxford, London, Newcastle, Sheffield, Edinburgh, Dundee, Manchester,
Torbay and Exeter, Supplementary Table 4). All patients provided written consent and either
a sample of blood or saliva, from which DNA was extracted according to standard protocols.
Research Ethics Committee approval was obtained prior to sample collection (Cambridge,
Oxford, London, Newcastle, Sheffield, Edinburgh, Dundee, Manchester, Torbay and Exeter
Local Research Ethics Committees). After QC (see below), we analyzed a total of 4682
samples, which were divided between the discovery panel (2361 samples) and replication
panel (2321 samples).
Controls—A total of 10,235 control DNA samples from 3 sources passed our QC filters
(see below). 5417 samples of the WTCCC2 common control set were used for the GWA
experiment. This comprised 2675 healthy blood donors recruited from the United Kingdom
Blood Service (UKBS), and 2742 samples from the 1958 Birth Cohort (1958BC) obtained
from EBV-transformed cell lines from individuals born in England, Wales and Scotland
during one week in 1958. The 4818 samples used as controls for the replication cohort were
recruited from the Wellcome Trust-funded People of the British Isles (PoBI) DNA
collection, obtained from rural populations throughout the British Isles, and from a further
independent set of DNA samples obtained from 1958BC. All of the control samples used
were from individuals with self-reported Caucasian ethnicity.
A summary of patients and controls is shown in Table 1 and Supplementary Table 4.
DNA sample preparation: Genomic DNA for all cases was shipped to the Sanger Institute,
Cambridge. DNA quality plus subject identity were validated using the Sequenom iPLEX
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assay designed to genotype 4 gender SNPs and 26 SNPs present on the Affymetrix array.
DNA concentrations were quantified using a PicoGreen assay (Invitrogen) and an aliquot
assayed by agarose gel electrophoresis. A DNA sample was considered to pass quality
control if the original DNA concentration was ≥50ng/ul, the DNA was not degraded, the
gender assignment from the iPLEX assay matched that provided in the patient data manifest
and genotypes were obtained for over 65% of the SNPs on the iPLEX.
GWA Genotyping
Samples were genotyped at Affymetrix's service laboratory on the Genome-Wide Human
SNP Array 6.0. For all samples passing Affymetrix's laboratory QC, raw intensities (from
the .CEL files) were renormalized within collections using CelQuantileNorm (see http://
outmodedbonsai.sourceforge.net/). These normalized intensities were used to call genotypes
with an updated version of the Chiamo software (see www.stats.ox.ac.uk/~marchini/
software/gwas/chiamo.html), adapted for Affymetrix 6.0 SNP data. The Chiamo algorithm
simultaneously calls genotypes for individuals in several collections; here it was applied to
15,068 individuals from five collections genotyped as part of the WTCCC2. Chiamo
generates posterior probabilities for each of the three possible genotypes plus a fourth class
of outliers. Our analyses use thresholded genotypes: for each individual, if one genotype had
posterior probability greater than 0.9, this was set as the genotype for that individual,
otherwise the genotype was set to be missing. After applying the QC filters described below,
this threshold led to a study-wide level of missing data of 0.20%.
An overlapping set of 4830 controls were also genotyped on the Illumina 1.2M chip as part
of a separate WTCCC2 project, and the 50,000 SNPs which are shared between that
platform and the Affymetrix 6.0 (used in this study) were used to evaluate genotype
accuracy. For the same QC thresholds and similar levels of missing data, discordance
between Chiamo and Illuminus, which we regard as an upper bound on genotyping error
rate, was 0.05857% for 1958BC and 0.07476% for UKBS.
We compared Chiamo to Birdsuite (the default Affymetrix calling algorithm applied on a
plate-by-plate basis as recommended in 33) by making genotype calls at different
confidence thresholds, and then plotting the fraction of calls made against concordance with
the Illumina genotypes (Supplementary Figure 2). The general trend is that, when matched
for the proportion of missing data, Chiamo has slightly higher concordance than Birdsuite.
We are therefore confident that Chiamo is an acceptable alternative to Birdsuite.
Replication Genotyping
In the replication stage, genotyping was carried out at the Sanger Institute using the
Sequenom iPLEX Gold assay. For one locus, the most associated SNP could not be
genotyped with this technology, so a perfect (r2 = 1 in all HapMap populations) proxy was
used instead. 19 SNPs (including 3 gender markers) were typed in a multiplex reaction; 15
passed experimental QC (one SNP with Hardy-Weinberg P value < 1 × 10−6 was discarded).
Samples with > 20% missing genotypes (n=300) were excluded; these samples are not
included in the tallies in Table 1.
Quality Control
Samples—As is now standard practice for GWAS studies, we excluded sets of individuals
whose genome-wide patterns of diversity are outliers compared to the bulk of those in the
study, and SNPs where there is evidence that genotype calls do not provide precise estimates
of genotype frequencies. Ignoring individuals and SNPs in this way throws away data
gained at some expense, but because they typically violate assumptions underpinning
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standard tests for association, the payback in terms of increased accuracy for these tests can
be substantial.
In order to try to obtain the maximally powerful set of samples and SNPs we attempted to
refine some standard QC practices. For all individuals we explicitly model the data as a
mixture of “normal” and “outlier” individuals for each of ancestry, missing data and
heterozygosity, and sex assignment.34 We fit each model in a Bayesian framework, and
exclude individuals whose posterior probability of belonging to the outlier class was above
0.5. This approach replaces (and we believe improves upon) the traditional concept of fixed
exclusion thresholds for parameters such as call rate, heterozygosity and ancestry. In total
413 case individuals and 567 control individuals were excluded from the analyses
(Supplementary Table 3).
To assess relatedness amongst study individuals we compared each individual with the 100
individuals they were most closely related to (on the basis of genome-wide levels of allele
sharing) and used a hidden Markov Model (HMM) to decide, at each position in their
genome, whether the two individuals shared 0, 1, or 2 chromosomes identical by descent.
This allows more refined assessment of the relatedness between individuals than do
genome-wide sharing statistics (for example, parent-child relationships can be distinguished
from siblings). We obtained a set of individuals with IBD < 5% by iteratively removing the
member of each pair of putatively related individuals with more missing genotypes.
SNPs—For each SNP we considered a measure of the (Fisher) information carried by the
genotype calls for the underlying allele frequency. Informally, this will decrease as the
number of individuals with low posterior probabilities for the most likely call increases, and
it can be thought of as a more refined measure of both missing data levels and minor allele
frequency (Supplementary Figure 3). The measure is calculated automatically by the
program SNPtest (www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html). SNPs were
removed if this information measure was below 0.98, or if the estimated MAF was below
0.01% (both calculated on the combined case-control data). 14.7% of SNPs were removed
by these criteria. Again, this approach appears to offer advantages over conventional SNP
filters, in excluding fewer SNPs for the same level of improved data quality. Because
associated SNPs are expected to be enriched in the tiny fraction of poorly performing
markers on these chips, we subsequently examined 155 cluster plots for SNPs with p <
1×10−5, and excluded 16 from further analysis as likely genotyping errors.
Supplementary Figure 4 provides QQ plots for the post-QC comparison of our two control
collections, and for association statistics based on the post-QC trend test comparing cases
and the combined control set. Both visual inspection, and the inflation statistic for each (λ =
1.037 and λ = 1.079 respectively), suggest that the QC filtered data provides a good basis
for association analyses.
Statistical Methods
We report p-values from 1-d.f. Cochran-Armitage tests for trend as implemented in the
software SNPTEST and PLINK.35 We also performed 2-d.f. genotypic tests to verify that
none of our associations show significant deviation from a multiplicative model, and two
marker logistic regressions to test for epistasis between associated markers. Effect size
estimates are based on replication samples only, and represent per-allele increase of risk in a
multiplicative model.
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Figure 1.
−log10(P) values from the 1 d.f. trend test. Alternating chromosomes shown in shades of
blue. SNPs with P < 1×10-5 which had not been previously reported are highlighted in
green. The three new loci identified in this study are noted.
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Figure 2.
−log10(P) values from the 1 d.f. trend test from three new loci, along with local
recombination rate estimated from HapMap data. Combined P values for replicated SNPs
are indicated with a red diamond.
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Table 1
Clinical details of cases and controls
GWAS Replication
cohort
CASES 2361 2321
Age at diagnosis a
Early onset (<18years) 5.9% (112) 6.5% (130)
Not early onset (>18years) 94.1% (1783) 93.5% (1861)
Median 33.4 35.2
Mean 36.3 38.2
Disease Extent b
Proctitis 17.9% (357) 15.1% (285)
Left sided 38.8% (774) 47.5% (897)
Extensive 43.3% (864) 37.4% (707)
Smoking at diagnosis c
Ex-smoker 36.7% (556) 30.3% (553)
Current smoker 10.8% (163) 16.4% (300)
Never smoked 52.5% (794) 53.2% (971)
Colectomy d
Yes 15.7% (266) 12.0% (226)
No 84.3% (1432) 88.0% (1660)
Colorectal cancer e 1.00% (23) 0.87% (20)
CONTROLS
Total 5417 4818
UKBS 2675 -
1958 Birth Cohort 2742 1952
POBI - 2866
a
Data available for 80% (GWAS) 86% (Replication),
b
Data available for 84% (GWAS) 81% (Replication),
c
Data available for 64% (GWAS) 79% (Replication),
d
Data available for 72% (GWAS) 81% (Replication),
e
Data available for 93% (GWAS) 99% (Replication).
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